Circulating tumor cells in colorectal cancer in the era of precision medicine
Hu, M., et al., Circulating tumor cells in colorectal cancer in the era of precision medicine
Hu, M., et al., Circulating tumor cells in colorectal cancer in the era of precision medicine
Bustos, M. A., et al. Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. J Clin Oncol 39, 2021 (suppl 15; abstr e16577); DOI: 10.1200/JCO.2021.39.15_suppl.e16577
Pascual, J., et al. CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study. J Clin Oncol 39, 2021 (suppl 15; abstr 1014) DOI: 10.1200/JCO.2021.39.15_suppl.1014
Luque-Tevar, M., et. Al. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. Front. Immunol., 23 March 2021 | https://doi.org/10.3389/fimmu.2021.631662
Saha, S. S., et. al. Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer. Cancers 2021, 13(6), 1420; https://doi.org/10.3390/cancers13061420
Mens, M. et al. Circulatory MicroRNAs as Potential Biomarkers for Stroke Risk. Stroke. 2021 FEB 10 . https://doi.org/10.1161/STROKEAHA.120.031543
Bustos, M. A., et al. Identification of cell-free microRNA signatures in pre-operative plasma from breast cancer patients. Cancer Res February 15 2021 (81) (4 Supplement) PS2-17; DOI: 10.1158/1538-7445.SABCS20-PS2-17
Wu., J. et al. Biological Age in Healthy Elderly Predicts Dementia in the Absence of a Brain Marker. Research Square. DEC 11.2020 DOI: https://doi.org/10.21203/rs.3.rs-119310/v1. Preprint
Johnson, K., et al. High-throughput detection of novel circulating miRNA biomarkers of non-alcoholic fatty liver disease. Litmus Project. Consortium Funded by the European Innovative Medicines Initiative.
Armand, P., et. al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. 2020 AUG 31. https://doi.org/10.1182/blood.2019004753
Pass, H., et. al. Mesothelioma Biomarkers: A Review Highlighting Contributions from Early Detection Research Network. Cancer Epidemiology, Biomarkers & Prevention. 2020 Jul 21. DOI: 10.1158/1055-9965.EPI-20-0083
Page last updated May 22, 2023